Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK
Stugeron 15 mg tablets.
| Pharmaceutical Form |
|---|
|
White circular tablet with S/15 on one side and JANSSEN on the other side. |
Each tablet contains 15 mg cinnarizine.
Excipients with known effect: Each tablet contains 160 mg lactose monohydrate and 15 mg sucrose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cinnarizine |
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction. |
| List of Excipients |
|---|
|
Lactose monohydrate |
PVC/Aluminium foil blisters
or
Polystyrene tubs with polyethylene caps
Each pack containing 15, 25, 100, 250 or 1000 tablets.
Not all pack sizes may be marketed.
Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK
PL 00242/5009R
Date of first authorisation: 14 September 1989
Date of latest renewal: 21 August 2001
| Drug | Countries | |
|---|---|---|
| STUGERON | Brazil, Cyprus, Ecuador, Estonia, Spain, Ireland, Lithuania, Malta, Mexico, Romania, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
